BioPharma

During the period of time from 2023 to 2029, the global market for cell and gene therapy Contract Development and Manufacturing Organization (CDMO) services is projected to grow at a compound annual growth rate (CAGR) of 17.5%. In 2022,...

Pharmaceutical businesses increasingly outsource their product development and manufacture to Contract Development and manufacture Organizations (CDMOs), which operate in a fragmented sector that is experiencing significant restructuring. However, a lot of CDMOs put their competitiveness at risk by not...

Thermo Fisher to acquire Clario Holdings, the clinical trial data firm, for $8.9 billion in cash is in news and the same has been announced by the companies on October 29. Clario is at present held by a shareholder group...

As the two Trump administration drug pricing deals find their place in the books and more that are likely on the way, the U.S. policy environment can very well soon stabilize for many Big Pharma companies. All this puts...

It is well to be noted that in 2025, a minimum of 14 major pharmaceutical companies across the world went ahead and announced plans to broaden their manufacturing presence in the U.S. so as to lessen the supply chain...

As the U.S. production investments continue to roll in 2025, LTS Lohmann, the German pharmaceutical technology specialist, is joining the table with a deal to boost its CDMO firepower in the U.S. Like many other contract manufacturing expansions that have...

As originally reported by the Straits Times and also shared by Reuters, the enforcement of US tariffs on pharma exports from Singapore is being deferred so as to provide stakeholders ample time to work out an amicable deal with the US...